Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Grainger hits full lease-up at Oxford development five months early

(Sharecast News) - Residential landlord and developer Grainger announced on Wednesday that it has achieved full lease-up of its new build-to-rent (BTR) scheme in Oxford some five months ahead of schedule. The Kimmeridge, Grainger's flagship 150-home development and its first BTR scheme in Oxford, achieved full lease-up in just seven months.

The scheme, which was expected to take 12 months to achieve full occupancy, experienced "exceptional leasing momentum" since launching in March, the company said.

The Kimmeridge, located west of Oxford's city centre, comprises over 2,000 square feet of shared amenity space, including a gym, lounge, co-working zones and outdoor areas.

Chief executive Helen Gordon called the milestone an "outstanding achievement".

"This success is testament to the dedication of our on-site teams, the quality of our customer experience, and the strength of our in-house leasing capabilities. As the first and only Build to Rent scheme in Oxford, The Kimmeridge reinforces our leadership in the sector and validates our strategic investment in this key location."

Grainger shares were up 0.2% at 184.8p by 0851 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.